Inclusion Criteria (from the main study):

• 50 years or older and may be either male or female and may be of any race
• Established diagnosis of geographic atrophy (GA) due to age-related macular degeneration (AMD)
• GA characteristics: GA area of between 1.25 mm² and 23 mm², with seventy percent of eyes having GA area ranging from 2.5 mm² to 17.5 mm². GA may be unifocal or multifocal. GA may be subfoveal or extrafoveal, with twenty-five percent of eyes having subfoveal GA. The presence of concurrent peripapillary atrophy will not exclude participants from participation
• Willing to participate as evidenced by signing the written informed consent

Additional Sub-study Inclusion Criteria:

• Early-stage GA defined as

  • GA area of between 1.25 mm2 and 23 mm2
  • GA may be unifocal or multifocal
  • GA may be subfoveal or extrafoveal
  • Concurrent peripapillary atrophy will not exclude participant from participation
  • Phakic and pseudophakic participants are eligible for enrollment, with phakic participants prioritized when feasible.

Exclusion Criteria (from the main study):

• Unable to tolerate ophthalmic imaging
• Presence of neovascular AMD on optical coherence tomography (OCT) as confirmed by an ophthalmologist
• Presence of significant media opacity preventing adequate retinal imaging
• Presence of concurrent retinal disease which may confound assessment

Additional Sub-study Exclusion Criteria:

• Ocular media opacity or other condition(s) that, in the opinion of the investigators, may preclude imaging.
• Individuals who, in the opinion of the investigator, are unable to tolerate study procedures or comply with study requirements.
• Prior or current treatment with intraocular injections for geographic atrophy (e.g., pegcetacoplan [Syfovre] or similar therapies) is not permitted.